ArticleFamilial cancer2019
Hereditary diffuse gastric cancer: cancer risk and the personal cost of preventive surgery.
Article in Familial cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Hereditary diffuse gastric cancer: updated clinical practice guidelines.The Lancet. Oncology · 2020Guideline
- Psychosocial Impacts of Prophylactic Total Gastrectomy for Hereditary Diffuse Gastric Cancer: A Narrative Review.Psycho-oncology · 2025Review
- Review
- Management Considerations in a Patient With a GermlineACG case reports journal · 2025Article
- How to measure quality of surgery as a component of multimodality treatment of gastric cancer.Annals of gastroenterological surgery · 2024Review
- Costs of Cancer Prevention: Physical and Psychosocial Sequelae of Risk-Reducing Total Gastrectomy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Patient-Reported Outcomes Measurement Information System in patients with gastrointestinal cancer: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- [Hereditary diffuse gastric cancer].Chirurgie (Heidelberg, Germany) · 2023Review
- Four cases of gastric adenocarcinoma and proximal polyposis of the stomach treated by robotic total gastrectomy.Surgical case reports · 2022Article
- Prophylactic laparoscopic total gastrectomy for gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): the first report in Asia.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022Article
- Diagnosis of MALT Lymphoma from Surveillance Endoscopy of a Patient with aGE Portuguese journal of gastroenterology · 2022Article
- Article
- Barriers and facilitators to CDH1 carriers contemplating or undergoing prophylactic total gastrectomy.Familial cancer · 2021Article
- Comparative Analysis of Clavien-Dindo Grade and Risk Factors of Complications after Dual-Port Laparoscopic Distal Gastrectomy and Hand-Assisted Laparoscopic Gastrectomy.Journal of oncology · 2021Article
- Quality of Life After Curative Resection for Gastric Cancer: Survey Metrics and Implications of Surgical Technique.The Journal of surgical research · 2020Review
- Epidemiology of Signet Ring Cell Adenocarcinomas.Cancers · 2020Article
- CDH1 (E-Cadherin) Mutation and Gastric Cancer: Genetics, Molecular Mechanisms and Guidelines for Management.Cancer management and research · 2019Review
- Gastric Signet-Ring-Cell Adenocarcinoma with Delayed Retroperitoneal Metastasis and Fibrosis.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Germline CDH1 mutation carriers are at risk for early-onset diffuse gastric cancer (DGC) and female carriers have an additional risk of lobular breast cancer. The reported literature GC risk of 70% has led to the recommendation for germline mutation carriers to undergo prophylactic total gastrectomy (PTG). The objective of this research was to examine post-surgical clinical outcomes and to identify which of the domains/symptoms from the European Organisation for Research and Treatment of Cancer QOL Questionnaire (EORTC QLQ-C30) were determinants of overall quality of life (QOL) in individuals undergoing PTG. Participants were recruited through multiple sources. Postsurgical clinical outcomes were obtained from hospital records. Participants completed validated questionnaires measuring generic and condition specific QOL (PROMIS, EORTC and SF 36v.II) at a single point in time. The mean QOL in this cohort was 70.6 (SD = 25.6), which is better than reference values from the general populations in USA and Canada Role and social function plus the symptoms anxiety, pain, taste, dyspnea and diarrhea were significant predictor variables for QOL (p < 0.05). Although this study reveals good overall QOL for individuals after PTG, attention should be given to managing symptoms as part of long term care to further enhance QOL. The function/symptom scores were associated with worse overall health and global health status and thus may mark a real need for more attentive post-surgical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.